Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,939 total articles
Alibaba's Q2 print scared the market because of a one-time surge in AI infrastructure spending and a regulatory fine, but underlying Cloud revenue growth of 45% and a reasonable market cap/P-E profile create a compelling swing trade. Enter near $121, stop at $105, target $160 over the next 45 trading days.
Lucid (LCID) trades like a beaten growth name with intact technology and a thin float. At a market cap near $1.9B and an enterprise value above $4.7B, the stock is pricing in persistent execution failure. Recent activism and a high-profile stake have re-opened the path to a supply-and-deliver turnaround. This trade targets a mid-term recovery to $1…
FedEx is trading near multi-month highs after steady operational recovery and market dynamics that potentially favor third-party carriers. The company posts strong free cash flow, a reasonable valuation (EV/EBITDA ~9.2, P/E ~18), and a modest dividend. This trade idea proposes a long entry at $338.00 with a $370.00 target over the next 45 trading d…
Progressive's July updates show premium growth slowing while combined ratios remain attractive and investment float continues to support earnings. At roughly $222, the stock trades at ~11x earnings with a strong capital position and healthy free cash flow. We propose a mid-term long trade to capture a re-rating if growth quality steadies and invest…
Kinder Morgan is consolidating near $31-$32 after a strong run. With a $71.4B market cap, a 3.7% yield, low leverage and a sizable backlog plus a new 35.1% stake in a $5B pipeline JV, the setup favors a measured long. This trade targets a re-test of the 52-week high and continued re-rating as expansion projects begin to convert to contracted cash f…
Hut 8 has moved from crypto mining to long-duration AI infrastructure contracts, including a headline 15-year, $9.8 billion lease for 352 MW. The market cap of roughly $10.5 billion and enterprise value near $10.96 billion leaves room for upside if contracted revenue and capacity monetization continue. This trade idea lays out a long-term (180 trad…
Cerebras (CBRS) sells an unusual, high-performance advantage: wafer-scale silicon optimized for ultra-low-latency inference. The stock trades well below its 52-week high after a post-IPO reset, but fundamentals show rapid revenue growth and strategic partnerships that can drive adoption in latency-sensitive AI applications. This is a high-risk, hig…
JOYY has rallied into fresh 52-week highs as investor sentiment around BIGO and leadership recognition improves. The stock looks buyable on momentum and an attractive ~6.4% yield, but technicals, rising short interest, and questions about cash quality argue for a disciplined, mid-term trade with a clear stop.
Agora is trading at a sub-$400M market cap while producing mid-teens revenue growth, sustained GAAP profitability, and rapid adoption of conversational AI products. At $4.145, the risk/reward favors a tactical long for investors willing to accept execution and China exposure risks. Entry $4.145, target $6.50, stop $3.50.
SM Energy ($35.75) looks positioned to outpace peers over the next 45 trading days as hedging friction fades, free cash flow remains robust ($757.8M), and valuation multiples are compressed (EV/EBITDA 4.44; P/E ~7). I prefer a mid-term long with an entry at $35.75, a stop at $30.50 and a target of $44.00 — a trade that captures oil upside while res…
Olin's share price has been punished by an unplanned vinyl chloride monomer plant shutdown and legal noise around the Huntsman merger. The disruption is a one-time cash hit of about $40 million to Q2 adjusted EBITDA with an estimated $20 million follow-through in Q3. At $17.29, the stock is trading near its 52-week low, yields 4.6%, and still gener…
Alvopetro Energy (ALVOF) trades at $7.10 with neutral momentum and a history of elevated short activity. Management has positioned the name as high-margin with a covered dividend. Liquidity and opacity are real risks, but the technical setup, modest RSI, and one-day days-to-cover give a defined risk-reward for a 45-trading-day swing trade.
Meta owns one of the largest AI compute footprints on the planet. If management moves aggressively to rent spare GPU capacity through inference/finetune marketplaces and third-party cloud deals, revenue upside and margin expansion can follow quickly. This is a mid-term trade: enter at $450, stop $390, target $540 on a 45 trading day horizon, with a…
Bonterra Energy (BNEFF) is an overtly levered oil & gas-style play trading on the OTC market around $4. Technicals are neutral-to-bullish, short interest has collapsed from spring highs and short-volume spikes show continued active shorting on rallies. If commodity prices stay supportive, this structure can produce a rapid move higher. This is a hi…
Clover Health is an actionable long thanks to accelerating Medicare Advantage membership, demonstrable AI-driven care improvements, improving free cash flow and a valuation that prices growth modestly. This trade idea lays out a mid-term plan centered on enrollment catalysts and recurring care-management economics while flagging regulatory, data an…
Stantec's $9.0B backlog, double-digit EPS growth and 17%+ adjusted EBITDA margins create a runway for continued organic growth. The stock trades at ~22.8x earnings with EV/EBITDA ~11.7x and an enterprise value of ~$9.34B, leaving room for upside if management converts backlog into revenue and sustains margins. We recommend buying STN with a clear e…
TG Therapeutics has transitioned from small-cap promise to commercial-stage execution. BRIUMVI's accelerating sales, upgraded 2025 guidance and an active product expansion roadmap justify upgrading the rating to Buy. This trade idea lays out an entry at the current level, a protective stop and a mid-term target driven by continued uptake and upcomi…
Symbotic is a hardware-led automation platform with a $22.3 billion backlog, 23% YoY revenue growth in Q2 2026, a material free cash flow stream, and recent software acquisitions that convert lumpy installations into higher-margin recurring value. We view the company as primed for an eFY2027 inflection in revenue conversion and margin expansion; in…
<p>Wheaton Precious Metals (WPM) reported record production and cash flow and looks to have its near-term growth pipeline effectively funded through existing streaming contracts and cash. That combination — demonstrated execution plus capital-light growth — supports a constructive trade. The plan below targets upside toward prior resistance while k…
AMC is trading at $2.66 with clear operational momentum from stronger attendance and a cleaner debt profile after recent refinancing. The stock can rally near-term, but the dominant risk remains share issuance. This trade sets a defined entry, stop and target while emphasizing active monitoring of outstanding shares and any new equity deals.
Ondas (ONDS) is growing fast: recent contract wins and an acquisition lift 2026 revenue targets well into the hundreds of millions, yet the company remains unprofitable and cash flow negative. For traders willing to accept volatility, a defined long trade with a clear stop and target offers attractive asymmetric upside while limiting downside if ex…
Sezzle's merchant-facing Sezzle Anywhere checkout and consumer-facing Sezzle Cash product create a path to disproportionate EBITDA growth as volumes scale. The market appears to be underestimating operating leverage from higher take rates, fixed-cost absorption, and cross-sell between products. This trade targets the re-rating that should follow ac…
Arteris (AIP) has pulled back from its 52-week highs and is carving a consolidation base around $23. The company's steady wins in automotive and cybersecurity IP, plus a recent acquisition and expanded Arm partnership, give a fundamental backdrop for a swing trade. Valuation is lofty vs. current profitability, so the trade is price-action driven wi…
Royalty Pharma (RPRX) is a cash-generating royalty vehicle with a diversified portfolio of commercial drugs and a growing development pipeline. At roughly $62 per share, the stock trades with an enterprise value to free cash flow of ~12x despite steady FCF of nearly $3.0B and visible catalysts (Asia expansion, Teva collaboration, new translational …
Navitas (NVTS) is a high-risk, high-upside trade: the company’s pivot from consumer GaN chargers to high-power, on-board data-center power delivery - accelerated by the acquisition of Claros - could turn a sub-$15M quarterly revenue stream into a meaningful AI-power platform. Market-cap and valuation metrics already price in extreme growth; this tr…
